262 related articles for article (PubMed ID: 23014660)
1. Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
Steinman RA; Brufsky AM; Oesterreich S
Breast Cancer Res; 2012 Sep; 14(5):213. PubMed ID: 23014660
[TBL] [Abstract][Full Text] [Related]
2. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
3. Anticancer activity of bisphosphonates in breast cancer.
Gnant M
Anticancer Agents Med Chem; 2012 Feb; 12(2):114-22. PubMed ID: 21864231
[TBL] [Abstract][Full Text] [Related]
4. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.
Santini D; Virzi V; Fratto ME; Bertoldo F; Sabbatini R; Berardi R; Calipari N; Ottaviani D; Ibrahim T
Curr Cancer Drug Targets; 2010 Feb; 10(1):46-54. PubMed ID: 20088792
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
Hershman DL; McMahon DJ; Crew KD; Cremers S; Irani D; Cucchiara G; Brafman L; Shane E
J Clin Oncol; 2008 Oct; 26(29):4739-45. PubMed ID: 18711172
[TBL] [Abstract][Full Text] [Related]
6. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V
Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates and breast cancer prevention.
Chlebowski RT; Col N
Anticancer Agents Med Chem; 2012 Feb; 12(2):144-50. PubMed ID: 21864227
[TBL] [Abstract][Full Text] [Related]
8. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
Gnant M; Clézardin P
Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
[TBL] [Abstract][Full Text] [Related]
9. Bone-modifying Agents (BMAs) in Breast Cancer.
Shapiro CL
Clin Breast Cancer; 2021 Oct; 21(5):e618-e630. PubMed ID: 34045175
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and breast cancer incidence and recurrence.
Chlebowski RT; Col N
Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
[TBL] [Abstract][Full Text] [Related]
12. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.
Hadji P; Coleman R; Gnant M; Green J
Ann Oncol; 2012 Nov; 23(11):2782-2790. PubMed ID: 22730099
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
Inoue S; Arai N; Tomihara K; Takashina M; Hattori Y; Noguchi M
Eur J Pharmacol; 2015 Aug; 761():44-54. PubMed ID: 25934567
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid: past, present and future roles in cancer treatment.
Saad F
Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
[TBL] [Abstract][Full Text] [Related]
16. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches.
Soki FN; Li X; Berry J; Koh A; Sinder BP; Qian X; Kozloff KM; Taichman RS; McCauley LK
J Cell Biochem; 2013 Jan; 114(1):67-78. PubMed ID: 22833499
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid for adjuvant use in patients with breast cancer.
Ressler S; Mlineritsch B; Greil R
Expert Rev Anticancer Ther; 2011 Mar; 11(3):333-49. PubMed ID: 21417849
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer: Zoledronic acid--more than just a bone drug.
Mathew A; Brufsky A
Nat Rev Clin Oncol; 2014 Oct; 11(10):564-5. PubMed ID: 25200411
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer.
Gallo M; De Luca A; Lamura L; Normanno N
Ann Oncol; 2012 Mar; 23(3):597-604. PubMed ID: 21551002
[TBL] [Abstract][Full Text] [Related]
20. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.
Hershman DL; McMahon DJ; Crew KD; Shao T; Cremers S; Brafman L; Awad D; Shane E
J Clin Endocrinol Metab; 2010 Feb; 95(2):559-66. PubMed ID: 20022990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
